The New Jersey Supreme Court heard arguments April 11 over whether hundreds of failure-to-warn claims against makers of generic Reglan—which is used to treat gastroesophageal reflux disease—are pre-empted by federal law.
A lawyer representing eight companies that manufacturer generic Reglan asked the court to overturn an Appellate Division ruling that said the claims are not pre-empted to the extent that those companies failed to comply with federal Food and Drug Administration requirements that they update their warning labels after the brand-name manufacturer has done so.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
